Prostate Cancer - Results from #25740

Internal radiotherapy techniques using radiolanthanide praseodymium-142: A review of production routes, brachytherapy, unsealed source therapy - Abstract July 20, 2011

Information needs of patients with prostate cancer : Pronounced differences between individuals after diagnosis of localised prostate carcinoma - Abstract July 20, 2011

Benefit assessment by the Federal Joint Committee : Assessment of treatment strategies for low risk prostate cancer - Abstract July 20, 2011

Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion - Abstract July 20, 2011

Editor's Commentary - Physician assessment of pretreatment functional status: A process-outcomes link July 20, 2011

The impact of nerve sparing on incidence and location of positive surgical margins in radical prostatectomy - Abstract July 19, 2011

Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: A randomized, placebo-controlled, double-blind phase 2 clinical trial - Abstract July 19, 2011

SRD5A polymorphisms and biochemical failure after radical prostatectomy - Abstract July 19, 2011

Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer - Abstract July 19, 2011

A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies - Abstract July 19, 2011

Initial high-grade prostatic intraepithelial neoplasia with carcinoma on subsequent prostate needle biopsy: Findings at radical prostatectomy - Abstract July 19, 2011

Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens - Abstract July 19, 2011

Editor's Commentary - A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range July 19, 2011

Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction - Abstract July 18, 2011

Effect on sexual function of a vacuum erection device post-prostatectomy - Abstract July 18, 2011

Saturation biopsies for prostate cancer detection: Effectiveness, safety and predictive factors - Abstract July 18, 2011

Expression of hedgehog pathway components in prostate carcinoma microenvironment: Shifting the balance towards autocrine signalling - Abstract July 18, 2011

The impact of PSA testing frequency on prostate cancer incidence and treatment in older men - Abstract July 18, 2011

Assessing response in bone metastases in prostate cancer with diffusion weighted MRI - Abstract July 18, 2011

Prostate-specific antigen 1.5-4.0 ng/mL: A diagnostic challenge and danger zone - Abstract July 18, 2011

Page 1288 of 1350